A B S T R A C T The effects of Fab fragments of highaffinity specific antibodies have been studied in a canine experimental model of lethal digitoxin toxicity. Selected antiserum from sheep immunized and boosted with a digoxin-serum albumin conjugate contained antibodies that cross-reacted with digitoxin with an average intrinsic association constant of 1.4 x 10"0 M-1 as determined by equilibrium dialysis.
A B S T R A C T The effects of Fab fragments of highaffinity specific antibodies have been studied in a canine experimental model of lethal digitoxin toxicity. Selected antiserum from sheep immunized and boosted with a digoxin-serum albumin conjugate contained antibodies that cross-reacted with digitoxin with an average intrinsic association constant of 1.4 x 10"0 M-1 as determined by equilibrium dialysis.
Rapid second-order association kinetics (kf = 3.7
x 106 M-1 per s) and slow dissociation kinetics (kr = 1.9 X 10-4 per s) were documented for the antibody-digitoxin complex. Eight dogs given 0.5 mg/ kg digitoxin intravenously developed ventricular tachycardia after 23±4 (SEM) min. Control nonspecific Fab fragments were then given. All animals died an average of 101+36 min after digitoxin administration. Another eight dogs given the same digitoxin dose similarly developed ventricular tachycardia after 28+3 min. This group then received a molar equivalent dose of specific Fab fragments intravenously over 3 min, followed by a 30-min infusion of one-third of the initial dose. All dogs survived. Conducted sinus beats reappeared 18+4 min after initial Fab infusion, and stable normal sinus rhythm was present at 54 ± 16 min. Plasma total digitoxin concentrations increased threefold during the hour after initial Fab infusion, while plasma free digitoxin concentration decreased to less than 0.1 ng/ml. Effects on digitoxin pharmacokinetics of these Fab fragments and the antibody population from which they were derived were further investigated in a primate species. Unlike common laboratory animals previously studied, the rhesus monkey was found to have a prolonged elimination half-life, estimated at 135
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Received for publication 20 January 1977 and in revised form 5 July 1977. and 118 h by radioimmunoassay and [3H]digitoxin measurements, respectively, similar to man and thus providing a clinically relevant experimental model. Intravenous administration of 2 mol of specific Fab fragments per mole of digitoxin 6 h after 0.2 mg of digitoxin produced a rapid 4.3-fold increase in plasma total digitoxin concentration followed by a rapid fall (t1 4 h) accompanied by a 14-fold enhancement of urinary digitoxin excretion over control values during the 6-h period after Fab was given. Analytical studies were consistent with increased excretion of native digitoxin rather than metabolites, and the glycoside was found in equilibrium dialysis studies to be excreted in the urine in Fab-bound form. Administration of 2 mol of specific antibody binding sites per mole of digitoxin as intact IgG caused a greater and more prolonged increase in plasma total digitoxin concentration, peaking 13-fold above control levels. In contrast to the effects of Fab, however, specific IgG reduced the rate of urinary digitoxin excretion substantially below control values. We conclude that Fab fragments of antibodies with high affinity for digitoxin are capable of rapid reversal of advanced, otherwise lethal digitoxin toxicity, and are capable of reducing the plasma half-life and accelerating urinary excretion of digitoxin.
INTRODUCTION
Severe digitalis toxicity resistant to conventional therapy remains an important clinical problem (1, 2) . Substantial experimental literature now exists demonstrating reversal of established effects of digoxin (3) (4) (5) as well as ouabain (6, 7) by specific antibodies or their Fab fragments, and Fab fragments of digoxin-specific antibodies have recently been used clinically to reverse toxicity after suicidal digoxin ingestion with high-grade atrioventricular block and intractable hyperkalemia (8) .
The cardiac glycoside digitoxin is used in 16-20% of digitalis-treated patients in the United States (9, 10) and is in even more common use in several other countries (2, 11, 12) . Substantial differences exist in plasma protein binding and pharmacokinetics of digitoxin compared with shorter-acting glycosides (13, 14) . The apolar nature of the digitoxin molecule results in a high degree of binding to serum albumin and presumably accounts as well for substantially higher myocardial tissue to medium glycoside concentration ratios compared with digoxin or ouabain in in vitro studies (15, 16) . Qualitative as well as quantitative differences in myocardial binding ofdigitoxin compared with more polar glycosides have been documented by Dutta et al. (17) . Potentially important pharmacodynamic differences, including differences in neurally mediated effects, have been observed in recent studies (18, 19) .
These differences in pharmacokinetics and pharmacodynamics of digitoxin raise serious questions regarding the extent to which prior studies of antibody reversal of digoxin toxicity can be extrapolated to digitoxin. Therefore, in the present study we have produced and characterized antibodies with high affinity for digitoxin and have examined in a canine experimental model the efficacy of Fab fragments of these antibodies in the reversal of advanced, potentially lethal digitoxin toxicity.
Because the dog, like other common subprimate laboratory animals, displays a pattern of digitoxin pharmacokinetics profoundly different from man (20), we determined that the rhesus monkey (Macaca mulatta) is a suitable experimental model for digitoxin pharmacokinetic studies in man. We then used this species to investigate the effects on digitoxin pharmacokinetics of these Fab fragments and the antibody population from which they were derived, and to test the hypothesis that excretion kinetics of a slowly excreted molecule could be enhanced by the administration of specific Fab fragments.
METHODS
Antibody production and characterization. Digoxin was conjugated to bovine serum albumin (BSA)' by periodate oxidation and Schiff's base formation and reduction (21, 22) as previously described (23) . Sheep were immunized with the BSA-digoxin conjugate in complete Freund's adjuvant and serially boosted and bled (4) . Preliminary studies identified an animal that responded to immunization with a high titer of antibodies that crossreacted strongly with digitoxin, and pooled antiserum from consecutive bleedings of this animal was used in subsequent experiments.
The IgG fraction was isolated by ammonium sulfate precipitation (24) , and Fab fragments were prepared by 'Abbreviations used in this paper: BSA, bovine serum albumin; PBS, phosphate-buffered saline.
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H. R. Ochs and T. W. Smith papain digestion as described by Nisonoff (25 In the second and third phases, additional blood samples were drawn 6.5, 7, 9, and 11 h after digitoxin administration (0.5, 1, 3, and 5 h after specific Fab or IgG injections, respectively). Spontaneously voided urine was collected during time intervals between 0 and 6, 6 and 12, 12 and 24, 24 and 48, 48 and 72, and 72 and 96 h after digitoxin administration. All plasma and urine samples were stored at -20°C until analyzed.
Plasma and urine digitoxin measurements. Digitoxin concentrations in plasma samples from dogs and in serum samples from rhesus monkeys were determined by radioimmunoassay as previously described (30) . Identical results were obtained for samples prepared as plasma or serum from either species, and are therefore reported as plasma values for convenience. Samples obtained after administration of specific antibody or Fab fragments were diluted 1:5 with PBS, heated for 1 h in a water bath at 100°C, and centrifuged for 30 min at 5,000 g to remove coagulated protein. Suitable amounts of the clear supernatant phase were then used to determine the total digitoxin content. Initial studies showed 95-98% recovery of known amounts of digitoxin by this method whether or not an excess of specific antibody or Fab fragments was present before the heating step. The results to be reported have not been corrected for these minor losses.
To determine the effect of [3H]digitoxin present in some doses administered to monkeys on the radioimmunoassay determination of unlabeled digitoxin, standards consisting of aliquots of suitable dilutions of the administered digitoxin mixture were used as well as conventional unlabeled standards. Comparison of results using these two types of standards documented the absence of measurable interference in the radioimmunoassay system by the relatively low specific activity of [3H]digitoxin administered to animals.
For the direct determination of 3H counts in samples, 0.2 ml ofurine or plasma was counted in 10 ml ofthe liquid scintillation medium described by Bray (31) . Quenching corrections were based on internal standards.
Separation of antibody-bound or Fab fragment-bound from free and albumin-bound digitoxin in plasma and urine samples was accomplished by equilibrium dialysis (23) . Dialyses were carried out in plastic chambers (Technilab Instruments, Inc., Pequannock, N. J.) with 1-ml volumes on either side of a sheet of washed dialysis tubing (average pore diameter 48 A, Arthur H. Thomas Co., Philadelphia, Pa.).
Plasma samples were dialyzed against equal volumes of normal rhesus or dog plasma, as appropriate, at 4°C with gentle mixing for a period of 6 days. Preliminary studies were carried out to ensure that equilibration had fully occurred by this time. Tritium counts on each side of the dialysis membrane were determined by liquid scintillation counting as described above. 1-ml urine samples were dialyzed against PBS using the method just described.
Since the digitoxin radioimmunoassay as used was limited to a sensitivity of about 1 ng/ml, 1-ml samples of plasma obtained from dogs [1] [2] [3] [4] [5] [6] h after specific Fab fragment administration were also equilibrated for 4 h with 2 ng of [3H]-digitoxin added in vitro and then dialyzed against 1 ml of normal dog plasma. This extended the sensitivity of detection of free digitoxin to levels of at least 0.05 ng/ml. Analytical studies of digitoxin and metabolites excreted in urine. Urine samples from rhesus monkeys were heated at 100°C for 1 h in a boiling water bath to denature excreted immunoglobulins or immunoglobulin fragments. 1 ml of urine was then added to 3 ml of dichloromethane (Aldrich Chemical Co., Inc., Milwaukee, Wis.) and mixed for 5 min with a Vortex-Genie (Scientific Industries, Inc., Bohemia, N. Y.) in a glass-stoppered tube (32) . After centrifugation, aliquots of aqueous and dichloromethane phases were subjected to liquid scintillation counting as described above.
After extraction, another aliquot of the dichloromethane phase was evaporated in a water bath at 50°C to dryness and the residue redissolved as described by Storstein (33) . Appropriate amounts ofthe tritiated digitoxin solution administered to animals in the second, third, and fourth experimental phases and [3H]digoxin (New England Nuclear) were identically treated and used as reference standards, applied in parallel with aliquots of dichloromethane extracts to silicagel chromatographic sheets (Eastman Chromagram, Eastman Kodak Co., Rochester, N. Y.). The sheets were run in cyclohexane:glacial acetic acid:chloroform, 49:2:49, developed with chloramine-T followed by heating, and read under ultraviolet light (34) . Tracks along which applied materials were chromatographed were then cut into 1-cm-long sections and subjected to liquid scintillation counting as noted above.
Pharmacokinetic analysis. Plasma pharmacokinetic data were fitted by computer using weighted nonlinear-squares regression analysis to a function of the form C = Aet-c + Be-"t where C = plasma concentration and t = time after the dose (35, 36) . The coefficients A, B, a, and 8 are "hybrid" quantities related to parameters of a two-compartment open model (37, 38) . Each residual error was weighted by a factor equal to the reciprocal of the concentration. Goodness of fit was assessed by comparison of actual data points to the computer-generated line to determine randomness of scatter. All analyses were then repeated using triexponential functions consistent with a three-compartment open model. The most appropriate model (biexponential for the data reported here) was chosen according to which yielded the smallest sum of squares of residual errors. The following pharmacokinetic parameters were then calculated: distribution half-life (tb), apparent elimination half-life (tip), volume of central compartment (V,), total apparent volume of distribution using the "area" method (Vd), and total clearance.
RESULTS
Characterization of antibodies with high affinity for digitoxin. A sheep immunized and repeatedly boosted with a digoxin-bovine serum albumin (BSA) conjugate produced antibodies that crossreacted strongly with digitoxin. The average intrinsic association constant (K0) for digitoxin of the pooled antiserum used in experiments reported in this paper, as determined by equilibrium dialysis and Scatchard analysis, was 1.4 x 1010 M-1 (Fig. 1 ). Association and dissociation rate constants for the reaction kf antibody + digitoxin antibody-digitoxin complex kr were kf = 3. (Table I) .
Animals treated with specific Fab fragments were observed over a 24-h period after the acute phase ofthe experiment, and all appeared healthy. Electrocardio- grams recorded 24 h after digitoxin administration showed normal sinus rhythm in all instances. Fig. 2 shows the effect of specific Fab fragments on plasma total digitoxin concentration. Each of the eight animals so treated showed a substantial increase in plasma total digitoxin concentration between the time of onset of ventricular tachycardia (just before Fab infusion) and 1 h after Fab infusion. The mean value of 762±68 ng/ml at onset of ventricular tachycardia was similar to that of 832±56 for control dogs, and increased to 2,143±144 ng/ml at 1 h (P < 0.0001).
As illustrated in Fig. 3 , peak plasma total digitoxin concentrations were present 1 h after initial Fab infusion and remained at these high levels over the ensuing 2 h. The only control animal surviving beyond 1 h after onset of ventricular tachycardia showed the expected decline in plasma concentration from 1,000 to 600 ng/ ml at 3 h (Fig. 3) . Despite these striking rises in plasma total digitoxin concentrations, free digitoxin levels in samples obtained from 1 to 6 h after specific Fab fragment administration were less than 1 ng/ml as determined by radioimmunoassay and were less than 0.1 nglml by direct measurement of dialyzable [3H]digitoxin added in vitro.
Digitoxin pharmacokinetic studies. The rhesus monkey was studied with the hope that the digitoxin elimination rate in this species would be similar to that in man. This proved to be the case. As shown in Fig. 4 , semilogarithmic plots of digitoxin plasma concentration vs. time showed a biexponential disappearance pattern. The mean distribution half-life (tb) ofthe three animals studied on two occasions by radioimmunoassay (phase 1 and phase 4) was 0.59 h (Table II) Effects ofspecific IgG administration on plasma digiinistration of itoxin concentrations. Administration of 2 mol of speoxin 6 h after cific binding sites per mole of digitoxin in the form of crease in total intact IgG resulted in a substantial increase in total )ntrol values. plasma radioactivity to a mean peak value 12.9-fold ien declined above pre-IgG infusion levels at the 28th hour of the experiment, as shown in Fig. 6 . This was followed by a gradual decline of plasma radioactivity until the 4th day, after which a more rapid fall was observed between the 4th and 9th days after specific IgG administration. Plasma levels of radioactivity were 10-fold higher 6 and 12 h after specific IgG administration when compared with the last sample obtained before antibody infusion. 2 wk after specific IgG administration, mean plasma radioactivity concentrations had returned to levels comparable with those observed in control experiments. Effects of specific Fab fragments on urinary excretion of digitoxin. Mean urinary excretion of radioactivity over 96 h in the absence of specific antibody or t7 9 11 14 Fab fragments totaled 11.7±2.4 ug, or 6% of the dose DAYS given, the largest amounts being excreted during the DOSE first and second 6-h collection periods (Fig. 7) . (Table IV) show a marked increase of the bound (nondialyzable) fraction of digitoxin during the 6 h after specific Fab administration to 98.7±0.5%, compared with a negligible value of 2.7±1.6% for urine excreted during the 6-h control period before Fab infusion. After specific IgG infusion, the small amount of 3H activity excreted increased from negligible percent bound values during the control (0-6 h) period to values in the 25-45% range, presumably related to small amounts ofimmunoglobulin or immunoglobulin fragments excreted.
It should be noted that the percent bound values for urine samples after Fab or IgG administration represent lower limits of actual binding since some degree of degradation of antibody or antibody fragments during collection and storage periods cannot be excluded.
Analytical studies of digitoxin and metabolites excreted in urine. To test the hypothesis that enhancement of3H excretion in urine after specific Fab infusion was due to excretion of native digitoxin bound to Fab fragments, further analytical studies were done. Dichloromethane extraction according to the method used showed that 99% of3H counts in digitoxin samples before administration to animals were extracted into the dichloromethane phase. Table V summarizes the percentages of dichloromethane-extractable radioactivity from urine obtained during the control experiments (phase 4) and after administration of specific Fab fragments and specific IgG (phases 2 and 3). After administration of specific Fab fragments, the percentage of extractable radioactivity increased from a control mean of 40% (phase 4) to 92% during the first 6-h period, gradually decreasing to control levels by the time of the 72-to 96-h urine sample. This is consistent with accelerated excretion of native digitoxin and excludes the possibility that 3H excretion was due to 3H (2, 39) . Due to its prolonged half-life compared with other glycosides (13) , digitoxin intoxication poses a special therapeutic problem. In a series of 115 patients treated for advanced (usually suicidal) digitalis intoxication, 96% had taken digitoxin and the resulting mortality was 22% (2) . Patients died as late as 4 days after injection of the drug, and doses as low as 3 mg were reported to cause mortality. Caldwell et al. have suggested a novel therapeutic approach using oral ingestion of a steroid-binding resin to interrupt enterohepatic cycling of digitoxin (40, 41) . This approach was highly effective in the rat (40) , a species with very active enterohepatic cycling of digitoxin, and some enhancement of digitoxin excretion was also documented in man (41) . However, since no specific antagonist of demonstrated clinical effectiveness in the setting of advanced toxicity has yet been described, therapy is restricted to symptomatic management of the clinical manifestations of digitalis toxicity.
To provide a more specific and effective therapeutic approach, the present study was undertaken to determine whether specific Fab fragments of antibodies that bind digitoxin with high affinity can reverse advanced, life-threatening digitoxin toxicity in a canine experimental model. The feasibility of this approach was suggested by earlier studies using digitalis-specific antibodies or their Fab fragments for reversal of glyco- side-induced effects in vitro (4) (5) (6) (7) (42) (43) (44) and toxic arrhythmias in vivo (3) (4) (5) 45 With regard to potential therapeutic use, the first requisite of an antibody population or the Fab fragments derived therefrom is high affinity and specificity for the drug molecule which is to be counteracted. In the case of cardiac glycosides such as digitoxin and digoxin, toxic effects may be manifest at free plasma concentrations of 10 nM or less (30, 48) . Antibody affinity constants must therefore be at least 109 or more if free glycoside concentrations are to be lowered to negligible levels without the use of excessive amounts of antibody, an issue of obvious importance if heterologous antiserum is used as the source of cardiac glycosidebinding immunoglobulin (5) .
In extending our earlier work to the reversal of digitoxin toxicity, we have taken advantage of the observation that selected antisera from animals immunized with BSA-digoxin conjugates contain antibody populations that strongly crossreact with digitoxin (23) . Among the first three sheep screened, we identified an animal that developed a high titer ofantibodies with a Ko value for digitoxin of 1.4 x 1010 M-1 by equilibrium dialysis, in satisfactory agreement with results of separate estimates of the kinetics of formation and dissociation of the hapten-antibody complex. The rapid second-order association kinetics ensure that the free fraction of serum digitoxin concentration will fall to less than 1 nM within a few seconds of the infusion of antibody in the amount used in the experiments reported here, assuming rapid mixing in the intravascular compartment. This rapid binding of digitoxin by antibody occurs in spite of extensive serum albumin binding of digitoxin (14) because of the very rapid dissociation rate of the digitoxin-albumin complex. It should be noted that the degree of digitoxin crossreactivity noted in the present studies cannot be expected for every digoxin-binding antibody population (23) .
The dose of0.5 mg/kg ofdigitoxin administered intravenously to dogs uniformly led to the death of the animals at a mean time of 101 min. Nonspecific Fab given to eight control animals did not protect from digitoxin toxicity. The administration of a small (33%) molar excess of specific Fab fragments not only prevented the death of all eight animals so treated, but also reversed cardiotoxic effects completely and led to reappearance of conducted sinus beats as early as 9-10 min after injection. This relatively rapid reversal of established advanced digitoxin toxicity confirms and extends previous experience with antibody reversal of established digoxin toxicity (3) (4) (5) as well as our initial clinical experience in the treatment of advanced digoxin toxicity with purified specific Fab fragments (8) .
A rapid increase in plasma total digitoxin levels took place within 30 min after the end of specific Fab infusion in all dogs (Fig. 2) ; during the subsequent 2 h, plasma concentrations did not change significantly (Fig. 3) . A similar plateau of serum total digoxin concentration after the initial rise after administration of specific Fab fragments lasted for 10 h in a patient treated for advanced digoxin toxicity after a massive suicidal ingestion of 22.5 mg of the drug (8) . The consistent increase in total digitoxin concentration in plasma observed after specific Fab administration in the studies reported here presumably reflects continuing removal of digitoxin from the tissues and sequestration in the extracellular space in an antibody-bound, pharmacologically inactive form, balanced by renal excretion ofthe Fab fragment-digitoxin complex. This mechanism was further supported by equilibrium dialysis studies showing free digitoxin concentrations of less than 0.1 nglml after specific Fab infusion in these dogs.
The prolonged half-life of digitoxin in man is associated with very slow excretion by the kidneys, which in turn is presumably due to the high degree of binding of digitoxin in the circulation by serum albumin. Lukas and DeMartino demonstrated that 97% of digitoxin at usual therapeutic concentrations is bound to serum albumin (14) . An effective approach to the specific treatment of advanced digitoxin intoxication, then, ideally should enhance excretion ofthe drug as well as neutralize its effects before excretion.
Canine digitoxin excretion, like that of usual laboratory animals such as the mouse, rat, and cat, is substantially more rapid than is the case in man (11, 13, 20) . The rhesus monkey (Macaca mulatta) was shown in the present studies to provide a more suitable model. The mean elimination half-times of 135 and 118 h found by two separate methods in this species ( Fig. 4 Prior studies ofthe effects of digoxin-specific IgG and Fab fragments on the pharmacokinetics of digoxin in the dog have documented substantial rises in plasma total digoxin concentration, with IgG causing about a sixfold greater rise than Fab (47) . Analogous results were observed in the present rhesus monkey experiments. Administration of 2 mol of binding sites per mole of digitoxin in the form of an IgG preparation resulted in a greater and substantially more prolonged increase in plasma total digitoxin levels compared with the response to an equal number of binding sites given as Fab fragments. The differences may be accounted for in part by a smaller distribution space of 160,000-dalton IgG molecules compared with 50,000-dalton Fab fragments, as well as by continuing urinary excretion of Fab fragments. The increases in plasma total digitoxin levels after both IgG and Fab administration were demonstrated in equilibrium dialysis studies to be due to high-affinity immunoglobulin binding, and were accompanied by rapid decreases in free digitoxin concentration to near-zero levels (Table III) .
Administration of IgG reduced the urinary excretion of radioactivity to 37% of control values. Ofthis amount more than 40% was not dialyzable, indicating that digitoxin was partly excreted in bound form, possibly to low molecular weight antibody fragments formed in vivo.
The serum ti of homologous and heterologous y-globulin injected into rabbits or guinea pigs has been shown to be between 4.2 and 6 days (49), and only small amounts of intact IgG were excreted in the urine. The reduction in urinary excretion of radioactivity after specific IgG administration was therefore not an unexpected observation.
Binding of digitoxin to Fab fragments appears to account for the initial half-life of digitoxin elimination from serum of 4 h (Fig. 5) . It has been reported that rabbit Fab fragments are excreted by the mouse, at least in part via the kidneys, with a half-time of 3.6 h (50). Although comparable data are not available for subhuman primates, the data of Janeway et al. (51) indicate elimination of immunoglobulin fragments of size and other properties similar to Fab by humans with a halftime of 5 h. One would therefore predict that relatively rapid renal elimination of sheep specific Fab fragments by the rhesus monkey kidney would enhance excretion of bound digitoxin, and this proved to be the case, as summarized in Figs. 7 and 8 . The high affinity of this population of Fab fragments for digitoxin ensures that, once filtered by the glomerulus, the Fab-digitoxin complex will not dissociate to a major extent and the digitoxin excreted in the urine remains predominantly bound in early urine samples collected after specific Fab administration (Table IV) . The analytical experiments using dichloromethane extraction and thin-layer chromatography suggest that administration of specific Fab fragments led to elimination ofnative digitoxin and not of metabolites.
Under the experimental conditions used in this primate model, digitoxin elimination rose 14-fold to 8% of the dose given over 6 h, compared with control values. When in severe digitoxin intoxication an even more pronounced acceleration of glycoside excretion is desirable, this may well be achieved by a constant infusion or repeated doses of purified Fab fragments over a more prolonged period oftime. This, to our knowledge, is the first demonstration of enhanced excretion of a drug by an immunoglobulin fragment and may represent only one example of a number of therapeutic opportunities wherein a higher clearance of a drug or hormone can be obtained.
In conclusion, the present studies demonstrate that high-affinity specific Fab fragments enhance urinary excretion of digitoxin, whereas administration of intact IgG leads to the opposite effect and retains the potentially toxic glycoside stores in the body. Taken together with the toxicity reversal studies in the dog, these data support the potential clinical use of purified specific Fab fragments in selected cases of advanced, lifethreatening digitoxin toxicity unresponsive to conventional therapy.
